HALO · Halozyme Therapeutics, Inc.
Market Cap
$12.37B
Shares
113.50M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $23,166,223 |
| Nicole LaBrosse | Senior Vice President, Chief Financial Officer | $4,578,814 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $4,531,568 |
| Cortney Caudill | Senior Vice President, Chief Operating Officer | $3,202,906 |
| Michael J. LaBarre | Former Senior Vice President, Chief Technical Officer | $2,053,642 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $12,741,421 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $5,394,865 |
| Nicole LaBrosse | Senior Vice President, Chief Financial Officer | $4,218,276 |
| Michael J. LaBarre | Senior Vice President, Chief Technical Officer | $3,038,441 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $11,820,858 |
| Nicole LaBrosse | Senior Vice President, Chief Financial Officer | $3,849,419 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $3,612,927 |
| Michael J. LaBarre | Senior Vice President, Chief Technical Officer | $3,243,941 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $9,696,978 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $3,740,202 |
| Nicole LaBrosse | Senior Vice President, Chief Financial Officer | $2,683,103 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Dannielle Appelhans | Director | Appointed | 2026-08-18 |
| Darren Snellgrove | Chief Financial Officer | Appointed | 2026-04-30 |
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
407 filings
386 filers
Visit website
Investor relations